MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP - Toronto Stock Exchange - CA58410Q2036 - Common Stock - Currency: CAD
Overall MDP gets a fundamental rating of 5 out of 10. We evaluated MDP against 34 industry peers in the Pharmaceuticals industry. While MDP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MDP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
MDP had a positive operating cash flow in the past year.
In multiple years MDP reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
MDP has a better Return On Assets (1.31%) than 82.35% of its industry peers.
MDP's Return On Equity of 4.31% is amongst the best of the industry. MDP outperforms 82.35% of its industry peers.
MDP has a better Return On Invested Capital (11.52%) than 94.12% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 7.89%.
The last Return On Invested Capital (11.52%) for MDP is above the 3 year average (9.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.31% | ||
| ROE | 4.31% | ||
| ROIC | 11.52% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
MDP has a Profit Margin of 2.07%. This is in the better half of the industry: MDP outperforms 79.41% of its industry peers.
The Operating Margin of MDP (11.00%) is better than 85.29% of its industry peers.
With an excellent Gross Margin value of 52.23%, MDP belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11% | ||
| PM (TTM) | 2.07% | ||
| GM | 52.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MDP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDP has more shares outstanding
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
MDP has an Altman-Z score of 0.59. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MDP (0.59) is better than 73.53% of its industry peers.
The Debt to FCF ratio of MDP is 1.74, which is an excellent value as it means it would take MDP, only 1.74 years of fcf income to pay off all of its debts.
MDP has a better Debt to FCF ratio (1.74) than 91.18% of its industry peers.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MDP has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. MDP outperforms 85.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | 0.59 |
ROIC/WACC1.23
WACC9.38%
2.3 Liquidity
MDP has a Current Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MDP (0.83) is worse than 85.29% of its industry peers.
A Quick Ratio of 0.47 indicates that MDP may have some problems paying its short term obligations.
MDP's Quick ratio of 0.47 is on the low side compared to the rest of the industry. MDP is outperformed by 73.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 900.00% over the past year.
Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -4.18% in the last year.
Measured over the past years, MDP shows a small growth in Revenue. The Revenue has been growing by 7.82% on average per year.
EPS 1Y (TTM)900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-4.18%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-4.65%
3.2 Future
The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.09% on average over the next years. This is quite good.
EPS Next Y-221.2%
EPS Next 2Y116.13%
EPS Next 3Y102.56%
EPS Next 5Y53.29%
Revenue Next Year-6.57%
Revenue Next 2Y5.72%
Revenue Next 3Y9.64%
Revenue Next 5Y10.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 27.36 indicates a quite expensive valuation of MDP.
82.35% of the companies in the same industry are more expensive than MDP, based on the Price/Earnings ratio.
MDP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.29.
The Forward Price/Earnings Ratio is negative for MDP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.36 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 94.12% of the companies listed in the same industry.
94.12% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.34 | ||
| EV/EBITDA | 4.41 |
4.3 Compensation for Growth
MDP has a very decent profitability rating, which may justify a higher PE ratio.
MDP's earnings are expected to grow with 102.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y116.13%
EPS Next 3Y102.56%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (7/7/2025, 7:00:00 PM)
3.01
-0.1 (-3.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.98%
Inst Owner ChangeN/A
Ins Owners7.25%
Ins Owner ChangeN/A
Market Cap97.10M
Analysts80
Price Target6.24 (107.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.09%
Min EPS beat(2)58.46%
Max EPS beat(2)69.73%
EPS beat(4)3
Avg EPS beat(4)31.55%
Min EPS beat(4)-100%
Max EPS beat(4)98.02%
EPS beat(8)5
Avg EPS beat(8)29.87%
EPS beat(12)8
Avg EPS beat(12)78.18%
EPS beat(16)9
Avg EPS beat(16)-34.63%
Revenue beat(2)1
Avg Revenue beat(2)3.19%
Min Revenue beat(2)-0.44%
Max Revenue beat(2)6.82%
Revenue beat(4)2
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-0.44%
Max Revenue beat(4)6.82%
Revenue beat(8)3
Avg Revenue beat(8)-1.09%
Revenue beat(12)6
Avg Revenue beat(12)0.63%
Revenue beat(16)8
Avg Revenue beat(16)0.96%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)5.28%
Revenue NQ rev (3m)4.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.36 | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | 3.34 | ||
| P/OCF | 2.96 | ||
| P/B | 1.36 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.41 |
EPS(TTM)0.11
EY3.65%
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.9
FCFY29.97%
OCF(TTM)1.02
OCFY33.8%
SpS4.59
BVpS2.21
TBVpS-1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.31% | ||
| ROE | 4.31% | ||
| ROCE | 16% | ||
| ROIC | 11.52% | ||
| ROICexc | 16.98% | ||
| ROICexgc | N/A | ||
| OM | 11% | ||
| PM (TTM) | 2.07% | ||
| GM | 52.23% | ||
| FCFM | 19.67% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 37.98% | ||
| Cap/Sales | 2.52% | ||
| Interest Coverage | 2.79 | ||
| Cash Conversion | 125.84% | ||
| Profit Quality | 948.29% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.59 |
F-Score5
WACC9.38%
ROIC/WACC1.23
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-221.2%
EPS Next 2Y116.13%
EPS Next 3Y102.56%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-4.18%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-4.65%
Revenue Next Year-6.57%
Revenue Next 2Y5.72%
Revenue Next 3Y9.64%
Revenue Next 5Y10.09%
EBIT growth 1Y-6.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.11%
EBIT Next 3Y62.77%
EBIT Next 5Y51.43%
FCF growth 1Y15.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.43%
OCF growth 3YN/A
OCF growth 5YN/A